Kiniksa(US:KNSA)2025-10-28 12:30Financial Performance - ARCALYST Q3 2025 revenue reached $180.9 million, representing approximately 61% year-over-year growth[10] - The company raised full-year 2025 net revenue guidance to between $670 million and $675 million, up from the previous guidance of between $625 million and $640 million[10] - Total prescribers of ARCALYST exceeded 3,825 as of Q3 2025[20] - Repeat prescribers of ARCALYST were approximately 1,070 as of Q3 2025[20] - Cash, cash equivalents, and short-term investments amounted to approximately $352.1 million as of September 30, 2025[29] ARCALYST Market and Usage - Approximately 20% of ARCALYST prescriptions are for patients on their first recurrence of pericarditis[16] - The majority of ARCALYST prescribing continues to come from the 14,000 multiple recurrence population[16] - Average total duration of ARCALYST therapy is approximately 32 months[20] - Payer approval rate for ARCALYST is greater than 90% of completed cases[20] Pipeline Development - KPL-387 received US Orphan Drug Designation for pericarditis, with Phase 2 data expected in the second half of 2026[10]